Zheng Quan Zhi Xing·2025-07-31 04:34Core Viewpoint - Baiyunshan is facing significant challenges with a projected 30% decline in net profit for 2024, marking the lowest level since 2017, primarily due to declining sales of key products and increased investment impairments [1][2]. Group 1: Investment and Fund Establishment - Baiyunshan plans to invest nearly 1.5 billion RMB to establish the second phase of the Guangzhou Traditional Chinese Medicine Fund, focusing on equity investments in the biopharmaceutical sector [1]. - Baiyunshan will hold a 99.9% stake in the fund, while Guangzhou Traditional Chinese Medicine Capital will hold 0.1% [1]. Group 2: Financial Performance - In 2024, Baiyunshan reported revenues of 74.993 billion RMB, a decrease of 0.69% year-on-year, with a net profit of 2.835 billion RMB, down 30.09% [2]. - The fourth quarter of 2024 saw a significant impact on annual performance, with revenues of 15.933 billion RMB, down 8.07% year-on-year, and a net loss of 323 million RMB [2]. Group 3: Product Performance - The commercial segment contributed significantly to revenue, generating 54.55 billion RMB, while the pharmaceutical manufacturing segment saw a revenue decline of 10.4% to 9.756 billion RMB [3]. - The sales of the high-margin product "Jingke" (Sildenafil) dropped by 13.17% in 2024, with inventory levels increasing by 49.78% [3]. Group 4: Impairment and Investment Issues - Baiyunshan recorded a 386 million RMB impairment on its long-term equity investment in Yaozong, which has been identified as a significant risk factor affecting overall profitability [3][5]. - The investment in Yaozong was initially made in 2017, and the company has since faced challenges due to rising costs and competitive pressures in the retail pharmacy sector [4][5].